Abstract:Background Rituximab(RTX), an anti-B-cell biological therapy, has been investigated in several clinical trials on antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV). RTX achieved high remission induction and sustained maintenance rates in patients with severe AAV, thereby challenging the cornerstone treatment of corticosteroids and cyclophosphamide followed by azathioprine[1][2]. In past clinical studies, RTX has been observed to be associated with a considerable number of adverse events, although the remission rate is high. Objectives This study aimed to study the efficacy and side effects of RTX in the treatment of AAV to provide help for drug selection and the care of AAV patients. Methods We systematically searched PubMed, EMBASE, Web of Science, Medline, Wanfang database, VIP, CNKI, and CBM databases from the establishment of the database to January 10, 2023. Cohort studies and case-control studies were included in the meta-analysis. We used the rate of all-cause death, remission and recurrence as the primary outcome for evaluating efficacy and safety. Severe infection and organ involvement(including urinary, cardiovascular, digestive, respiratory, nervous, ear, nose, throat, and skin) were secondary outcome indicators. Results A total of 90 cohort studies, including 17,929 patients with AAV treated with RTX, were included in our study. The summary results indicated a 9.6%(95%CI: 0.071-0.123) risk of all-cause death in patients with AAV treated with RTX. Symptoms were relieved in 84.9%(95%CI: 0.803-0.890) of patients with medication, 41.4%(95%CI: 0.353-0.475) with complete remission and 45.0%(95%CI: 0.401-0.498) with partial remission. 10.7%, 14.2%, and 26.0% of patients faced disease recurrence in 6 months, 12 months, and 24 months respectively. Further, to compare the efficacy of RTX in the phase of induced remission and maintenance treatment, we conducted a subgroup analysis. The studies of accessible treatment stage were included. The results showed that RTX therapy during maintenance treatment presented lower all-cause mortality(5.4% vs. 9.1%) and a higher remission rate(86.1% vs.77.7%). For secondary results, RTX has a significant impact on all systems. The frequency of severe infection in patients treated with RTX was 25.6%(95%CI: 0.187-0.325). Ear, nose, and throat were the earliest and most affected organs(ES=57.7%, 95%CI: 0.433-0.721), and gastrointestinal diseases were the least common(ES=6.3%, 95%CI: 4.2%-8.5%). Conclusion Our results showed that using RTX in the treatment of AAV is efficacy, especially during maintenance treatment. Prevention should be carried out for different organ systems as early as possible to achieve personalized treatment. References [1]Guillevin, L. et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med 371, 1771-1780, doi:10.1056/NEJMoa1404231 (2014). [2]Raffray, L. & Guillevin, L. Rituximab treatment of ANCA-associated vasculitis. Expert Opin Biol Ther 20, 899-910, doi:10.1080/14712598.2020.1748597 (2020). Acknowledgements: NIL. Disclosure of Interests None Declared.

Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides

Long-Term Rituximab Use to Maintain Remission of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Trial

Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial

Rituximab As Maintenance Therapy Following Remission Induction in Relapsing or Refractory Systemic Lupus Erythematosus.

POS1164 CLINICAL OUTCOMES OF ANCA-ASSOCIATED VASCULITIS PATIENTS RECEIVING RITUXIMAB INDUCTION AND MAINTENANCE THERAPY: SYSTEMATIC REVIEW AND META-ANALYSIS OF LARGE OBSERVATIONAL STUDIES

Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis

Relapses and serious adverse events during rituximab maintenance therapy in ANCA-associated vasculitis: a multicentre retrospective study

Reduced-dose versus high-dose glucocorticoids added to rituximab on remission induction in ANCA-associated vasculitis: predefined 2-year follow-up study

[Anti-Neutrophil Cytoplasmic Antigens (ANCA)-associated vasculitis: Current therapeutics]

Rituximab treatment in ANCA-associated vasculitis patients: outcomes of a real-life experience from an observational cohort

Mycophenolate mofetil versus cyclophosphamide for inducing remission of ANCA vasculitis with moderate renal involvement.

Development and Validation of a Simulation Model for Treatment to Maintain Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis

Analysis of treatment outcomes in patients with antineutrophil cytoplasmic antibody-associated vasculitis on rituximab therapy

Update on targeted treatments for ANCA-associated vasculitis

Effectiveness and safety of rituximab in severely relapsed antineutrophil cytoplasmic antibody-associated vasculitis: a retrospective analysis of a Japanese multicentre cohort from the J-CANVAS

Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial

Two Decades Rituximab Therapy in Anti-Neutrophil Cytoplasmic Antibody Associated Vasculitis

Combination Therapy With Rituximab and Cyclophosphamide for Remission Induction in ANCA Vasculitis

The effect of discontinuation of maintenance therapy in Chinese patients with MPO-ANCA associated vasculitis who were in long-term stable remission

Comparison of mycophenolate mofetil and cyclophosphamide treatment in patients with ANCA associated vasculitis

#5390 INTENSIFIED B CELL DEPLETION THERAPY IN ANCA-VASCULITIS WITH SEVERE RENAL IMPAIRMENT AS COMPARED TO CONVENTIONAL IMMUNOSUPPRESSION